Q1 26 EPS
$-0.13
BEAT +58.51%
Est. $-0.31
Q1 26 Revenue
$38.2M
BEAT +382.65%
Est. $7.9M
vs S&P Since Q1 26
-18.0%
TRAILING MARKET
WVE -12.0% vs S&P +6.1%
Market Reaction
Did WVE Beat Earnings? Q1 2026 Results
Wave Life Sciences delivered a standout first quarter for fiscal 2026, posting results that ran well ahead of Wall Street expectations across every key metric. The Cambridge-based RNA medicine company reported a loss of $0.13 per share, beating the c… Read more Wave Life Sciences delivered a standout first quarter for fiscal 2026, posting results that ran well ahead of Wall Street expectations across every key metric. The Cambridge-based RNA medicine company reported a loss of $0.13 per share, beating the consensus estimate of $0.31 by 58.51%, while revenue of $38.25 million cleared the $7.92 million analyst estimate by 382.65% and surged 316.9% year over year from $9.18 million, with the GSK collaboration serving as the primary engine behind that dramatic top-line expansion. The revenue influx helped narrow the operating loss to $31.30 million from $49.80 million a year ago, even as R&D spending climbed to $47.44 million. With $544.59 million in cash on hand, management expects its runway to extend into the third quarter of 2028. Looking ahead, Wave plans to initiate the Phase 2a portion of the INLIGHT trial for obesity candidate WVE-007 in Q2 2026, while regulatory feedback on WVE-006 in AATD and an NDA submission for WVE-N531 in Duchenne muscular dystrophy are both targeted for 2026.
Key Takeaways
- • Revenue increase to $38.2 million from $9.2 million driven by GSK collaboration revenue recognition
- • Interest income nearly doubled to $5.3 million due to larger cash balance
- • Net loss narrowed significantly from $46.9 million to $26.1 million year-over-year
WVE Forward Guidance & Outlook
Wave expects its cash and cash equivalents of $544.6 million to fund operations into the third quarter of 2028, excluding potential future milestone payments from its GSK collaboration. The company plans to initiate the Phase 2a multidose portion of the INLIGHT trial of WVE-007 in Q2 2026, with combination and maintenance studies also expected to begin in 2026. Data from the RestorAATion-2 trial of WVE-006 (400 mg monthly and 600 mg single dose cohorts) will be presented at an investor webcast during the ATS International Conference in May 2026, with regulatory feedback on a potential accelerated approval pathway expected mid-2026. A CTA filing for WVE-008 is on track for 2026, and an NDA submission for WVE-N531 in DMD is planned for 2026.
WVE YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
“We're accelerating WVE-007 to the next stages of development following the improvements in body composition already observed in the Phase 1 portion of our INLIGHT trial, including profound reductions in harmful visceral fat, along with favorable safety and potential for once to twice yearly dosing. This quarter, we expect to initiate the Phase 2a portion of INLIGHT in individuals with higher BMI and excess fat. Given WVE-007's mechanism of targeted lipolysis, we believe this portion of the study can deliver even more pronounced improvements in body composition. Importantly, we've designed the Phase 2a study to assess additional biomarkers of cardiometabolic health, which will inform WVE-007's broad potential across obesity and multiple indications, including MASH, type 2 diabetes, and cardiovascular disease. We also plan to rapidly initiate investigation of WVE-007 in both the combination and maintenance settings soon thereafter.”
— Paul Bolno, Q1 2026 Earnings Press Release
WVE Earnings Trends
WVE vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
WVE EPS Trend
Earnings per share: estimate vs actual
WVE Revenue Trend
Quarterly revenue: estimate vs actual
WVE Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $-0.31 | $-0.13 | +58.51% | $38.2M | +382.65% |
| Q4 25 MISS FY | $-0.26 | $-0.30 | -13.51% | $17.2M | +9.98% |
| FY Full Year | — | $-1.21 | — | $42.7M | — |
| Q3 25 MISS | $-0.30 | $-0.32 | -8.18% | $7.6M | -27.73% |
| Q2 25 MISS | $-0.28 | $-0.31 | -9.00% | $8.7M | -9.78% |
| Q1 25 MISS | $-0.26 | $-0.29 | -13.46% | $9.2M | -19.09% |